As the human race has evolved over time there have been several positive advancements in technology, commerce, and medicine that have been beneficial for society. However, there has been negative impacts that have accompanied those advancements. Our lives have become saturated with various tasks leaving little time leftover for exercise, proper nutrition and rest. Furthermore, the typical western diet consisting of an excessive amount of high fat and high-sugar, overly processed foods has led to excessive weight gain in some individuals.
At the same time, there is tremendous pressure in our society to be fit and lean. There is no shortage of companies catering to this demographic. The supplement market is so oversaturated with fat burners that many are overwhelmed by all the options. Unfortunately, all of these products over promise and deliver mediocre results. Even fat burner supplements from reputable companies are only mildly effective. As a result, the consumer has devolved into a state of cynicism and has drifted further away from their target weight. So what can be done to TR1UMPH over this barrier? Your friends at Olympus Labs are here to help you.
The DemiGods at Olympus Labs have conjured up a fat burning formula so advanced and aggressive your guilt will turn into pride as you evolve past genetic barriers to reveal a fitter version of yourself. Olympus Labs presents IGNIT3; an explosive fat incinerator! IGNIT3 is like nothing you have seen before, it is truly a revolutionary product. So what differentiates IGNIT3 from all the other fat burners out there? It is quite simple actually, Olympus Labs underwent an extensive research process to develop the ultimate fat burning blend, backed by clinical science. Several ingredients were considered and rejected because they did not satisfy our strict criteria of Innovation, Value and Results.
A supplement formula does not necessarily need to contain a new ingredient to be innovative. Although IGNIT3 includes relatively new and emerging ingredients like Eria Jarensis and J. Regia, the innovation lies within the combination of mechanisms of action IGNIT3 targets. The two aforementioned ingredients, Eria Jarensis and J. Regia are combined with Rauwolfia Serpentina in the Adrenergic Enhancing Trifecta blend that act upon the sympathetic nervous system aid in fat loss. We are excited as you are about that blend alone, but IGNIT3 targets four more pathways for a total of 5 synergistic pathways. The AMPlified Fat Incinerating Matrix with St. John’s Wort Extract, Gynostemma Pentaphyllum Leaf Extract and Caffeine targets the activated protein kinase (AMPK) to regulate metabolic function.
The Brown Fat + Thyroid Modulating & Total PPAR Domination blend covers the remaining three pathways. The blend consists of Aframomum Melegueta which activates Brown Adipose Tissue (BAT) which leads to thermogenesis, Ginger Root Extract for BAT activation and to regulate the thyroid hormone and Olive Leaf Extract which also activates BAT. Olive Leaf Extract and the final two ingredients, Sesamol and Haematococcus Pluvialis Extract all activate peroxisome proliferator-activated receptors (PPARs) to stimulate your metabolism and adipogenesis, the inhibition of fat storage in the body.
Take a quick glance at the product label of IGNIT3 and it is clear that this is not your average fat burner. Although you may recognize some of the ingredients from some other fat burning supplements, we challenge you to look closer at those formulas. Is it just 1-2 effective ingredients accompanied with poor performing and cheap fillers? Are the doses comparable? IGNIT3 utilizes 11, yes 11, beneficial ingredients at effective doses backed by clinical studies. But that’s not all, as always, Olympus Labs uses superior extracts for superior results.
That is exactly where other fat burner supplements fail, they contain random ingredients that simply do not complement each other. The manufacturers of said products clearly have no regard for the time and hardwork you put into looking your best. Their sole motivation is to profit from your misfortune. Olympus Labs would never compromise our morals and resort to such a practice. IGNIT3 targets 5 different pathways to ensure you obtain noticeable results. Olympus Labs is here to help you get back on track towards your weight loss goals. We have generated the spark to IGNIT3 your thermogenic furnace!
Adrenergic Enhancing Trifecta:
The advances in the field of medicine over the years has made new and exciting supplements available. We utilize three such ingredients in the Adrenergic Enhancing Trifecta blend; Rauwolfia Serpentina, Eria Jarensis and J. Regia. Adrenergic substances act upon the sympathetic nervous system which activates a sequence of nerve cell firing and chemical release of epinephrine (adrenaline), norepinephrine in the blood stream. The release of these chemicals can be utilized to aid in fat loss. Although there is limited clinical data on these ingredients, the anecdotal feedback is quite compelling, which formed the basis for their inclusion in IGNIT3.
Rauwolscine, also known as α-yohimbine, is an alkaloid of Rauwolfia Serpentina. It is an alpha-2 adrenergic antagonist, that causes increases in epinephrine and norepinephrine in the blood stream. When exposed to epinephrine and norepinephrine, alpha-2 receptor sites inhibit lipolysis, the breakdown of fat. Since rauwolscine acts as an alpha-2 blocker it reverses that action and stimulates lipolysis.
There are a few studies that confirm that rauwolscine binds with comparable nanomolar affinity to alpha 2 adrenoceptors and the nonadrenergic 5-HT autoreceptors sites in human frontal cortex membranes. The studies all concluded that rauwolscine has agonistic properties at the level of 5-HT autoreceptors
Eria Jarensis is an orchidaceae alkaloid, meaning it is derived from the orchid family of flowering plants. It is the only known plant derivative to contain N-phenethyl dimethylamine. Phenethylyamines (PEA) Increases levels of epinephrine and norepinephrine that can stimulate beta-adrenergic receptors located on adipose (fat) tissue to release fatty acids into circulation as a fuel source. However, PEAs effects are relatively short-lived because the compound is broken down by the MAO-B enzyme within hours. N-Phenethyl dimethylamine rectifies that issue so you can realize the thermogenic benefits without having to dose the ingredient every few hours for it to be effective as you would PEA. Therefore, Eria Jarensis has become popular as a supplement for its energy and thermogenic benefits.
Regia is a source of various psychoactive alkaloids and Olympus Labs uses a custom extract of it in IGNIT3. It is no longer a secret, J. Regia is truly an amazing and potent ingredient. But what may not be quite as well known is how multidimensional J. Regia is. It was included in the best pre-workout on the market, CONQU3R UNLEASHED and the pre-productivity supplement, ELIX1R for its focus and mood elevating benefits. However, It is also been observed to provide extreme energy and can suppress appetite, therefore J. Regia can be useful when dieting.
AMPlified Fat Incinerating Matrix:
The AMPlified Fat Incinerating Matrix will IGNIT3 your thermogenic furnace with 900mg of St. John’s Wort Extract, 450mg of Gynostemma Pentaphyllum Leaf Extract and 300mg Caffeine. This matrix was specifically designed to stimulate AMP-activated protein kinase (AMPK). AMPK is an enzyme that regulates metabolic function. During periods of energy stress, AMPK promotes glucose transport and glycolysis for ATP production, while it is thought to inhibit anabolic glycogen synthesis by suppressing the activity of glycogen synthase (GS) to maintain the energy balance in muscle. Paradoxically, chronic activation of AMPK causes an increase in glycogen accumulation in skeletal and cardiac muscles. That amazing energy you feel from IGNIT3? That would be the fat being incinerated!
St. John’s wort extract is herb that grows natively in areas of Asia and has been used for centuries for health purposes. The leaves and flowers of this herb contain hypericin and pseudohypericin. It is has been shown that both compounds specifically inhibit protein kinase C and shows antiproliferative activity against mammalian cells. St. John’s wort extract helps improve energy and alertness. It can also relieve stress and anxiety. However we included St. John’s wort extract in IGNIT3 because it has been identified as an inhibitor of adipogenesis.
Adipogenesis is a multistep process of cell differentiation where pre-adipocytes become mature adipocytes, or insulin-sensitive cells. An increase in the number and size of adipocytes causes white adipose tissue (WAT) to expand and this can lead to obesity, hence the reason inhibition of adipogenesis is beneficial.
St. John’s Wort is a significant CYP3A4 inducer, an enzyme involved in the metabolism of several pharmaceuticals drugs. If you are using any other pharmaceuticals, consult a medical professional before supplementation of St. John’s Wort to ensure those other drugs do not interact with CYP3A4.
In animal studies St. John’s Wort (SJW) extracts inhibited insulin-sensitive glucose uptake in mature fat cells. In follow-up studies, the effects of SJW have been further investigated on insulin action in both murine and human fat cells. It was shown that SJW also reduced insulin-sensitive glucose uptake in human adipocytes. Moreover, two constituents of SJW, hypericin (HI) and hyperforin (HF) were shown to modulate adipocyte development and insulin action in mature adipocytes. These studies concluded that SJW has significant effects on adipogenesis and insulin-stimulated glucose uptake.
In a double blind, randomized, placebo-controlled study, 23 subjects overweight healthy adults were separated into 1 of 3 groups. Group A consumed 975 mg of C aurantium extract, 528 mg of caffeine, and 900 mg of St. John’s Wort daily for 6 weeks; group B received a maltodextrin placebo; and group C received nothing and served as the control group. During the trial the participants were given guidance by a registered dietitian to follow an 1800-kcal/d American Heart Association Step One diet and performed a 3-day/week circuit training exercise program under the supervision of an exercise physiologist. During the exercise sessions, subjects achieved approximately 70% of age-predicted maximum heart rate. Compared with subjects in the placebo and control groups, subjects in the treatment group lost a significant amount of body weight (1.4kg). They also lost a significant amount of body fat (an average change of 2.9%). In terms of actual fat loss, group A lost a significant amount (3.1kg), whereas the control group demonstrated a tendency toward fat loss. The researchers concluded that the combination of C aurantium extract, caffeine, and St. John’s Wort is safe and effective when combined with mild caloric restriction and exercise for promoting both body weight and fat loss in healthy overweight adults.
Gynostemma Pentaphyllum leaf extract, sometimes referred to as Southern Ginseng, is a herb that has been typically been used in Asian countries as a treatment for type 2 diabetes and inflammation. Do not confuse Gynostemma Pentaphyllum with Panax Ginseng as they are two very different herbs. Gynostemma Pentaphyllum stimulates fat oxidation and glucose uptake by activating AMP-activated protein kinase (AMPK).
Caffeine increases focus, mental alertness and reduces symptoms of fatigue due to its ability to produce higher dopamine levels in areas of the brain that are linked to “attention”. It also increases energy expenditure and lipolysis which made it an easy choice to include in IGNIT3.
A double-blind study in healthy subjects who had a moderate habitual caffeine consumption investigated the effect on placebo and 100, 200, and 400 mg oral caffeine on energy expenditure, plasma concentrations of substrates and hormones, blood pressure, and heart rate. Caffeine dose dependently increased energy expenditure and the thermogenic response was positively correlated with the response in plasma caffeine (r = 0.52; p less than 0.018), plasma lactate (r = 0.79; p less than 0.000001), and plasma triglyceride (r = 0.53; p less than 0.02). These results indicate an increase in energy expenditure and thermogenic response from caffeine consumption.
A study was conducted to determine the relationship between paraxanthine (caffeine’s major dimethylxanthine metabolite) and free fatty acid (FFA) mobilization after intravenous caffeine administration. 10 men received a dose of 4mg of caffeine per kilogram of lean body mass. Venous blood samples were obtained before dosing and at multiple time intervals (5, 10, 15, 30, 45, 60, 90, 120, 150, and 180 minutes). Serum levels of FFA, glycerol, caffeine, and paraxanthine were determined in duplicate. Concentrations of FFA and glycerol were corrected for plasma volume changes. A high negative correlation was seen between decreases in caffeine and increases in FFA (r = -0.90) and a high positive correlation was seen between the appearance of paraxanthine and FFA (r = 0.93). It was concluded that paraxanthine may play a role in increased lipolysis after caffeine administration in humans.
Brown Fat + Thyroid Modulating & Total PPAR Domination:
As promised, IGNIT3 targets every major fat burning pathway. IGNIT3 includes 240mg of Aframomum Melegueta, 40mg of Ginger Root Extract and 400mg of Olive Leaf Extract for their ability to activate Brown Adipose Tissue (BAT). BAT is responsible for thermogenesis under normal conditions or during a dieting phase. It regulates whole-body energy expenditure and body fat content. Even though it activates BAT, our prime motivation in including Olive Leaf Extract is its ability to act upon the thyroid which can increase energy expenditure and ameliorate obesity, diabetes and metabolic disorders. Furthermore, Olive Leaf Extract has been shown to act upon the PPARγ receptor.
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors of the nuclear hormone receptor superfamily. There are three subtypes: PPARα, PPARγ, and PPARβ/δ. Activation of PPAR-α reduces triglyceride levels and is involved in regulation of energy homeostasis. Activation of PPAR-γ causes insulin sensitization and enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism. IGNIT3 includes 200mg of Sesamol for its activation of PPAR-α and PPAR-γ and 240mg of the PPAR-α activator, Haematococcus Pluvialis Extract.
6-paradol is an extract of Grains of paradise (Aframomum Melegueta) a species of the ginger family, Zingiberaceae. It is an aromatic ketone which gives it a pungent, peppery taste. 6-paradol is known to activate thermogenesis in BAT and thus is a beneficial ingredient for the regulation of weight loss and weight maintenance. Furthermore, it has been shown that 6-paradol is a more potent paradol analogue compared to others with longer acyl chain lengths which is exactly what you want to IGNIT3 the metabolic furnace.
A single-blind, randomised, placebo-controlled, crossover designed study was conducted with 19 healthy males to examine the effects of the Grains of paradise (GP, Aframomum melegueta) extract on whole-body energy expenditure (EE) and to analyse its relation to BAT activity in men. Results from a test method that assesses BAT activity showed considerable uptake into the adipose tissue of the supraclavicular and paraspinal regions (BAT positive) in twelve subjects. The remaining seven showed no detectable uptake (BAT negative). Within 4 weeks after the examination, whole-body EE was measured at 27°C before and after oral ingestion of GP extract (40 mg). The resting EE of the BAT-positive group did not differ from that of the BAT-negative group. After GP extract ingestion, the EE of the BAT-positive group increased within 2 h to a significantly greater (P<0·01) level than that of the BAT-negative group. Placebo ingestion produced no significant change in EE. These findings suggest that oral ingestion of GP extract increases whole-body EE through the activation of BAT in human subjects.
Ginger contains pungent phenolic substances collectively known as gingerols. 6-Gingerol is the major pharmacologically-active component of ginger. 6-gingerol is known to have anti-cancer, anti-inflammatory and anti-oxidative properties. Ginger and its constituents have also been reported to possess gastro-protective and cholesterol-lowering properties. However, it is included in IGNIT3 because it can stimulate the peroxisome proliferator-activated receptor δ (PPARδ). As a PPARδ agonist, 6-gingerol will causes weight loss through increased energy expenditure and the browning of white fat.
A study was conducted to examine the antiobesity effect of dietary ginger extract (GE) in vivo with mice and the mechanism of action in vitro with human skeletal muscle myotubes. In the in vitro component of the study, 6-shogaol and 6-gingerol acted as specific PPARδ ligands and stimulated PPARδ-dependent gene expression in cultured human skeletal muscle myotubes. An analysis of cellular respiration revealed that pretreating cultured skeletal muscle myotubes with GE increased palmitate-induced oxygen consumption rate, which suggested an increase in cellular fatty acid catabolism. The mice treated with GE showed increased energy expenditure and diet-induced obesity was attenuated. GE also increased the number of Type I muscle fibers, improved running endurance capacity and upregulated PPARδ-targeted gene expression in skeletal muscle and the liver. These results demonstrated that sustained activation of the PPARδ pathway with GE attenuated diet-induced obesity and improved exercise endurance capacity by increasing skeletal muscle fat catabolism. These results showed that 6-Shogaol and 6-gingerol may be responsible for the regulatory effects of dietary ginger on PPARδ signaling.
A 30 day study was conducted where high-fat diet (HFD) induced obese rats were treated orally with a daily dose of gingerol (25, 50 and 75 mg kg-1). A lorcaserin, a pharmaceutical weight loss drug, treated group (10 mg kg-1) was included for comparison. The levels of body weight, glucose, lipid profile and insulin, insulin resistance, leptin, amylase and lipase were increased significantly (P < 0.05) in HFD rats. Rats treated with gingerol and fed a HFD showed significantly (P < 0.05) decreased glucose levels, body weight, leptin, insulin, amylase, lipase plasma and tissue lipids when compared to normal control. The effect at a dose of 75 mg kg-1 of gingerol was more pronounced than that of the dose 25 mg kg-1 and 50 mg kg-1 . The lorcaserin-treated group also manifested similar effects to those of gingerol. These results indicate that supplementation with 6-gingerol may suppress obesity induced by a high fat diet and it might be a promising adjuvant therapy for the treatment of obesity and its complications.
Oleuropein is the major phenolic compound found in the leaves and oil from olives. It possesses antioxidant, anti-inflammatory and anti-atherogenic effects and suppresses proliferation of fat cells in the body. Oleuropein has also been found to exert anti-adipogenic effects through direct inhibition of PPARγ. Furthermore, it has been shown to enhance thermogenesis by increasing the uncoupling protein 1 (UCP1) in Inducible Brown Adipose Tissue (IBAT) and urinary noradrenaline and adrenaline secretions.
The antiobesity effect of oleuropein was investigated in mice that were fed with a normal diet, HFD-40% fat of total energy) and HFD-supplemented with 0.03% oleuropein for 10 weeks. Oleuropein significantly reduced HFD-induced body weight gain and visceral adiposity. Oleuropein also significantly reversed the HFD-induced elevations of adipogenic related gene expression involved in WNT10b- and galanin-mediated signalings in adipose tissue of mice. Consistent with the in vivo findings, oleuropein dose-dependently suppressed lipid accumulation in 3T3-L1 cells during preadipocyte differentiation. Additionally, exposure of the 3T3-L1 preadipocytes to oleuropein resulted in a marked attenuation of the secreted frizzled-related protein 2 (WNT inhibitor) or galanin (galanin receptor agonist) induced cellular lipid accumulation. These results suggest that oleuropein has a protective effect against HFD-induced adiposity in mice and can reduce body weight gain and visceral adiposity.
A study with 3T3-L1 (mouse) cells treated with oleuropein between 10 and 400 μM concentrations did not affect activity of PPARα or PPARβ/δ. In fact, PPARγ activity, either basal or rosiglitazone activated, was inhibited by oleuropein. These findings indicate that oleuropein may exert anti-adipogenic effects through direct inhibition of PPARγ transcriptional activity.
A study was conducted to measure the degree of thermogenesis in interscapular brown adipose tissue (IBAT), and noradrenaline and adrenaline secretions in rats when supplemented with a phenolic compound, oleuropein, in extra virgin olive oil (EV-olive oil). In Experiment 1, rats were given a high-fat diet (control diet) with the oleuropein supplementation of 1, 2 or 4 mg/kg of diet (0.1, 0.2 or 0.4% oleuropein diet, respectively). After 28 d of feeding, body weight, perirenal adipose tissue, epididymal fat pad, and plasma triglyceride, free fatty acid and total cholesterol concentrations were reduced by the 0.1, 0.2 or 0.4% oleuropein diet and were significantly lowest in rats fed the 0.4% oleuropein diet, as compared with those of rats fed with the control diet. The content of uncoupling protein 1 (UCP1) in IBAT and urinary noradrenaline and adrenaline excretions were significantly higher in rats fed the 0.1 or 0.2% oleuropein diet, as compared with those of rats fed with the control diet, although there were no significant differences in rats fed the 0.4% oleuropein diet. In Experiment 2, the effects of oleuropein on noradrenaline and adrenaline secretion were evaluated. The intravenous administration of oleuropein and oleuropein aglycone significantly increased plasma noradrenaline and adrenaline concentrations. Furthermore, oleuropein aglycone induced the secretions of noradrenaline and adrenaline about ten fold more potently than oleuropein. These results indicate that oleuropein enhances thermogenesis by increasing the UCP1 content in IBAT and noradrenaline and adrenaline secretions in rats.
Sesamol is a phenol derivative of sesame oil. It is generated from sesamolin by roasting sesame seeds or through a bleaching process of sesame oil. It is a natural potent antioxidant and anti-inflammatory ingredient that has been found to have antimutagenic properties and is an efficient scavenger of the entire range of reactive oxygen species (ROS), validated by several tests. This is an important characteristic due to the fact that increased oxidative stress and inflammation is the direct cause of the development and proliferation of cardiometabolic syndrome (CMetS) in obese individuals. In addition, sesamol has been found to be a PPAR-γ modulator.
An animal study was conducted to determine the potential role of sesamol in chronic high-cholesterol/high-fat diet (HFD)-induced cardiometabolic syndrome (CMetS). Rats were fed with HFD (55% calorie from fat and 2% cholesterol) for 60 days to induce obesity, dyslipidemia, insulin resistance (IR), hepatic steatosis and hypertension. On the 30th day, rats with total cholesterol >150 mg/dl were considered hypercholesterolemic and administered sesamol 2, 4 and 8 mg/kg per day for the next 30 days. Sesamol treatment decreased IR, hyperinsulinemia, hyperglycemia, dyslipidemia, TNF-α, IL-6, leptin, resistin, highly sensitive C-reactive protein (hs-CRP), hepatic transaminases and alkaline phosphatase, along with normalization of adiponectin, nitric oxide and arterial pressures in a dose-dependent fashion. Increased TBARS, nitrotyrosine and decreased antioxidant enzyme activities were also amended in HFD rats. Similarly, sesamol normalized hepatic steatosis and ultrastructural pathological alteration in hepatocytes, although the effect was more pronounced at 8 mg/kg. Furthermore, hepatic PPARγ, PPARα and e-NOS protein expressions were increased, whereas LXRα, SERBP-1c, P-JNK and NF-κB expression were decreased by sesamol treatment. Based on these findings sesamol may be an effective treatment for CMetS.
Haematococcus Pluvialis is a freshwater species of chlorophyta, a division of green algae. It contains the antioxidant Astaxanthin which can lower adiponectin levels, a protein that is involved in regulating glucose levels and the breakdown of fatty acid levels.
In an SHR/NDmcr-cp (cp/cp) rat model oral administration of dietary astaxanthin oil (ASX-O) of 50 mg/kg/day for 22 weeks induced a significant reduction in arterial blood pressure in SHRcp. It also significantly reduced the fasting blood glucose level, homeostasis index of insulin resistance (HOMA-IR), and improved insulin sensitivity. The results also showed an improved adiponectin level, a significant increase in high-density lipoprotein cholesterol, a significant decrease in plasma levels of triglycerides, and nonesterified fatty acids. Additionally, ASX showed significant effects on the white adipose tissue by decreasing the size of the fat cells. These findings suggest that ASX improves insulin resistance through an increase of glucose uptake and by regulating the level of circulating lipid metabolites and adiponectin.
61 non-obese subjects with fasting serum triglyceride of 120-200mg/dl and without diabetes or hypertension participated in a placebo-controlled study to validate previous astaxanthin studies in animals. The subjects were randomly selected to receive astaxanthin in doses of 0, 6, 12, 18 mg/day for 12 weeks. Body mass index (BMI) and LDL-cholesterol were unaffected at all doses, however, triglyceride decreased, while HDL-cholesterol increased significantly. Multiple comparison tests showed that 12 and 18 mg/day doses significantly reduced triglyceride, and 6 and 12 mg doses significantly increased HDL-cholesterol. Serum adiponectin was increased by astaxanthin (12 and 18 mg/day), and changes of adiponectin correlated positively with HDL-cholesterol changes independent of age and BMI. These results suggest that astaxanthin consumption improves triglyceride and HDL-cholesterol in conjunction with increased adiponectin in humans.